434 related articles for article (PubMed ID: 15790787)
1. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.
Parmar S; Smith J; Sassano A; Uddin S; Katsoulidis E; Majchrzak B; Kambhampati S; Eklund EA; Tallman MS; Fish EN; Platanias LC
Blood; 2005 Oct; 106(7):2436-43. PubMed ID: 15790787
[TBL] [Abstract][Full Text] [Related]
2. Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons.
Lekmine F; Uddin S; Sassano A; Parmar S; Brachmann SM; Majchrzak B; Sonenberg N; Hay N; Fish EN; Platanias LC
J Biol Chem; 2003 Jul; 278(30):27772-80. PubMed ID: 12759354
[TBL] [Abstract][Full Text] [Related]
3. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.
Parmar S; Katsoulidis E; Verma A; Li Y; Sassano A; Lal L; Majchrzak B; Ravandi F; Tallman MS; Fish EN; Platanias LC
J Biol Chem; 2004 Jun; 279(24):25345-52. PubMed ID: 15056660
[TBL] [Abstract][Full Text] [Related]
4. Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells.
Lal L; Li Y; Smith J; Sassano A; Uddin S; Parmar S; Tallman MS; Minucci S; Hay N; Platanias LC
Blood; 2005 Feb; 105(4):1669-77. PubMed ID: 15471950
[TBL] [Abstract][Full Text] [Related]
5. Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells.
Yoon P; Giafis N; Smith J; Mears H; Katsoulidis E; Sassano A; Altman J; Redig AJ; Tallman MS; Platanias LC
Mol Cancer Ther; 2006 Nov; 5(11):2815-23. PubMed ID: 17121928
[TBL] [Abstract][Full Text] [Related]
6. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
7. A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation.
Prabhu S; Saadat D; Zhang M; Halbur L; Fruehauf JP; Ong ST
Oncogene; 2007 Feb; 26(8):1188-200. PubMed ID: 16936779
[TBL] [Abstract][Full Text] [Related]
8. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
Ly C; Arechiga AF; Melo JV; Walsh CM; Ong ST
Cancer Res; 2003 Sep; 63(18):5716-22. PubMed ID: 14522890
[TBL] [Abstract][Full Text] [Related]
9. Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway.
Carayol N; Katsoulidis E; Sassano A; Altman JK; Druker BJ; Platanias LC
J Biol Chem; 2008 Mar; 283(13):8601-10. PubMed ID: 18223253
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
[TBL] [Abstract][Full Text] [Related]
11. Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells.
Marley SB; Lewis JL; Schneider H; Rudd CE; Gordon MY
Br J Haematol; 2004 May; 125(4):500-11. PubMed ID: 15142121
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance.
Zhang M; Fu W; Prabhu S; Moore JC; Ko J; Kim JW; Druker BJ; Trapp V; Fruehauf J; Gram H; Fan HY; Ong ST
Mol Cell Biol; 2008 Oct; 28(20):6496-509. PubMed ID: 18694961
[TBL] [Abstract][Full Text] [Related]
13. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
14. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
15. ANG II activates effectors of mTOR via PI3-K signaling in human coronary smooth muscle cells.
Hafizi S; Wang X; Chester AH; Yacoub MH; Proud CG
Am J Physiol Heart Circ Physiol; 2004 Sep; 287(3):H1232-8. PubMed ID: 15317677
[TBL] [Abstract][Full Text] [Related]
16. Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor.
Bhattacharya S; Zheng H; Tzimas C; Carroll M; Baker DP; Fuchs SY
Blood; 2011 Oct; 118(15):4179-87. PubMed ID: 21821707
[TBL] [Abstract][Full Text] [Related]
17. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
Klejman A; Rushen L; Morrione A; Slupianek A; Skorski T
Oncogene; 2002 Aug; 21(38):5868-76. PubMed ID: 12185586
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells.
Nimmanapalli R; Bali P; O'Bryan E; Fuino L; Guo F; Wu J; Houghton P; Bhalla K
Cancer Res; 2003 Nov; 63(22):7950-8. PubMed ID: 14633726
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.
Quentmeier H; Eberth S; Romani J; Zaborski M; Drexler HG
J Hematol Oncol; 2011 Feb; 4():6. PubMed ID: 21299849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]